Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Cancer (2)
- Atezolizumab (1)
- Bevacizumab (1)
- Buprenorphine (1)
- CME (1)
-
- Cancer Center (1)
- Cognitive Behavioral Therapy. (1)
- Colon cancer (1)
- Colorectal pathology (1)
- Colorectal screening (1)
- EOCRC (1)
- Early onset cancer (1)
- Early onset colorectal cancer (1)
- HCC (1)
- Harm Reduction (1)
- Healthcare (1)
- Hematologic malignancy (1)
- Hepatocellular carcinoma (1)
- Hospital (1)
- Liver (1)
- MAT (1)
- Medical ethics (1)
- Medication Assisted Therapy (1)
- Multiple myeloma (1)
- Oncology (1)
- Opioid (1)
- Opioid Use Disorder (1)
- Pain (1)
- Primary care (1)
- Readmission Rates (1)
- File Type
Articles 1 - 5 of 5
Full-Text Articles in Medicine and Health Sciences
Early Onset Colorectal Cancer: Research, Trends & Challenges, Sarah E. Smith
Early Onset Colorectal Cancer: Research, Trends & Challenges, Sarah E. Smith
Capstone Showcase
Early onset colorectal cancer (EOCRC) incidence and mortality are rising in a global trend, contrasting with improvements seen in late-onset colorectal cancer (LOCRC). EOCRC appears to differ in presentation, histology, and pathology from LOCRC painting concerns of a more aggressive tumor profile. With incidence steadily climbing, there is still lacking awareness and guidance on screening for EOCRC. This article aims to provide background on EOCRC including epidemiology, risk factors, and traits, as well as to explore methods for adjusting provider screening criteria to combat this concerning trend.
Increasing Inpatient Volume And Efficiency Through Decreasing Readmission Rates At Fox Chase Cancer Center, Courtney Pokallus, Islande Victorin
Increasing Inpatient Volume And Efficiency Through Decreasing Readmission Rates At Fox Chase Cancer Center, Courtney Pokallus, Islande Victorin
Capstone Showcase
This paper outlines the semester long strategic plan created by Islande Victorin and Courtney Pokallus for Fox Chase Cancer Center. This strategic plan includes a background of the organization, SWOT analysis on the organization, identification of potential problems and a gap analysis, a strategic summary, and all outlines and plans for the strategic plan.
In Patients With Hepatocellular Carcinoma (Hcc) (P), Is Bevacizumab With Atezolizumab (I) More Effective Than Sorafenib (C) In Long-Term Clinical Prognosis (O)?, Joon Lee
Capstone Showcase
Hepatocellular carcinoma (HCC) is the third leading cause of cancer death globally. China contributes to half of the global incidence of liver cancer, with about 70-85% being HCC. Definitive treatment for this condition would be surgical resection with liver transplant but for obvious reasons, the majority of affected patients are unable to meet the necessary criteria. Sorafenib is a form of chemotherapy that has been the mainstay treatment of HCC since its approval in 2007. More recently, the combination of Bevacizumab and Atezolizumab has shown greater efficacy in the treatment of unresectable HCC. Additionally, this new combination therapy shows favorable …
Detecting Multiple Myeloma In The Primary Care Setting, Anna Schweidler
Detecting Multiple Myeloma In The Primary Care Setting, Anna Schweidler
Capstone Showcase
Multiple myeloma (MM) is a hematological malignancy arising from differentiated B-lymphocyte white blood cells called plasma cells. Hematological malignancies are the fourth most diagnosed cancers, composing approximately 9% of all cancer diagnoses. Specifically, multiple myeloma attributes to approximately 2% of cancer diagnoses in the United States2. MM incidence has increased significantly over the past years, increasing 40% in the United States and 126% globally from 1990-2016 2. Affecting 7.0 out of every 100,000 people2, multiple myeloma is considered a rare form of blood cancer. Many strides have been made in the treatment of multiple myeloma …
Opioid Use Disorder: The Timeline For Medication Assisted Therapy, Alexander Cristofori
Opioid Use Disorder: The Timeline For Medication Assisted Therapy, Alexander Cristofori
Capstone Showcase
Opioid Use Disorder is patterns of opioid use leading to withdrawal, giving up important life events in order to use opioids, and excessive time spent using opioids, to name a few diagnostic criteria. The clinical progression of the disorder involves periods of acute exacerbation and remission that are cyclic in nature. Treatment is most effective when it includes both pharmacological and psychosocial modalities, referred to as medication assisted therapy (MAT). Three drugs used commonly in MAT-based treatment for OUD from oldest to newest include Methadone, Buprenorphine-naloxone, and Naltrexone. Treatment program models that prioritize total abstinence from the addictive substance attached …